Speaker Profile

M.D., M.B.A, Managing Partner, Section 32; Chairman, Foundation Medicine
Biography

Dr. Pellini is Managing Partner of Section 32, a venture fund that invests in companies and inventors that are changing the way humans use technology and the way technology betters humanity. Previously, he served as CEO of Foundation Medicine (NASDAQ:FMI) from May 2011 until he transitioned to Chairman in February 2017. He currently serves as a member of the Board of Directors for Tango Therapeutics, Singular Genomics, Adaptive Biotechnologies, the Personalized Medicine Coalition, and the Mission Hospital Foundation, in addition to his Board Chair position with Foundation Medicine. As a physician with more than 20 years of executive experience with companies at the forefront of clinical diagnostics and genomics, Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. Dr. Pellini is a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Cancer Institute (Provident/St. Joseph Health). Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.

Session Abstract – PMWC 2019 Silicon Valley

Session Synopsis: VC activity is booming in healthcare. As such, investments have reached record-breaking numbers, including in the AI/ML sector. This panel will discuss the future of the investment sector, how AI/ML is shaping healthcare, and what to expect in the years to come.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!